Top lung cancer developments in 2025? My take: 2025 wasn’t about a single disruptive moment. It was about consolidation, maturation, and a few long-awaited signals finally turning solid. 1) MARIPOSA delivers OS Amivantamab lazertinib demonstrates an overall survival benefit over osimertinib in first-line EGFR-mutant NSCLC. Toxicity, logistics, and sequencing still matter—but this is now a real OS-based conversation, not just a PFS debate. 2) FLAURA2 confirms upfront intensification can matter Osimertinib chemotherapy shows improved OS vs osimertinib alone. Reinforces that combination strategies can deepen benefit, at the cost of complexity and tolerability. “Best first-line EGFR strategy” is now legitimately plural. 3) HER2 finally matters clinically Accelerated approvals for zongertinib and sevabertinib in HER2-mutant NSCLC. Oral TKIs, meaningful response rates, and a credible path beyond antibody-drug conjugates alone. 4) EGFR exon 20 keeps inching forward Sunvozertinib approved post-platinum. Incremental progress, but still meaningful in a historically difficult molecular subset. 5) c-MET ADC enters routine practice Telisotuzumab vedotin approved for MET-high NSCLC. Expression-based biomarkers and ADCs are now firmly embedded in lung cancer decision-making. 6) A genuine advance in SCLC Tarlatamab converts to full approval in platinum-refractory ES-SCLC with a survival benefit. Rare, and important. 7) Companion diagnostics become unavoidable HER2 TKD, EGFR exon 20, MET expression—therapy is increasingly inseparable from the assay used to define eligibility. Testing strategy is now a core clinical decision. 8) Combination immunotherapy reality check ATR inhibition durvalumab misses OS (LATIFY). A reminder that biological plausibility still has to survive Phase 3. 9) AI moves from novelty to infrastructure Improved CT nodule detection, risk stratification, and workflow support. Still assistive, not autonomous—but no longer theoretical. 10) Direction of travel is clear More rare targets, more ADCs, OS gains in EGFR-mutant disease, slow but meaningful progress in SCLC—and increasing pressure on systems to deliver precision care at scale. Bottom line: 2025 didn’t reinvent lung cancer. It made several long-promised ideas finally defensible at the OS level. That’s quieter progress—but it’s the kind that lasts. #LCSM @SylvesterCancer @IASLC @myESMO @lungoncdoc @Latinamd @COlazagasti @Jani_Chinmay @NarjustFlorezMD @DrJNaidoo @StephenVLiu @EddieSantosMD @RManochakian @LuisRaezMD @uicc

ctDNA analysis in the CALGB/SWOG 80702 @JAMAOnc (presented at #GI25) ✅CALGB/SWOG 80702: Adjuvant FOLFOX ± celecoxib for stage III colon cancer ✅Adding celecoxib improved DFS & OS in ctDNA patients, irrespective of PIK3CA mutational status (no benefit in ctDNA-) 👉Does ctDNA supersede PIK3CA status as a biomarker? Validation warranted. jamanetwork.com/journals/jam… @OncoAlert

New Team Ovary study out in Gynecologic Oncology! 🎉 Adding nivolumab to neoadjuvant chemo in advanced ovarian cancer was safe & feasible — 75% achieved complete resection. Read here 👉 doi.org/10.1016/j.ygyno.2025…

🚨Our new paper is out today in Nature! We show that SARS-CoV-2 mRNA vaccines can sensitize tumors to immune checkpoint blockade (ICI) — revealing that clinically available RNA vaccines may act as potent immune modulators. nature.com/articles/s41586-0…

Ehi, @giubileif , ti ricordi? Il 30 ottobre 2019 al Senato fu approvata la Commissione Segre contro i fenomeni di intolleranza, razzismo, antisemitismo e istigazione all'odio e alla violenza. I tuoi amichetti non solo si astennero dal voto, ma al momento degli applausi per Liliana Segre rimasero seduti, indifferenti e ibernati. Come la vostra coscienza.

Today's Nobel Prize for Physiology or Medicine relates to research on regulatory T cells nobelprize.org/prizes/medici… For readers interested in harnessing the biology of regulatory T cells to treat disease, here's a comprehensive review nature.com/articles/s41573-0… rdcu.be/eJHU8

Nature research paper: Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA go.nature.com/46zRY9L

Online Now: Immune memory shapes ovarian cancer recurrence dlvr.it/TMDJbJ

We, the Weizmann Institute of Science community, deeply mourn the passing of Prof. Zelig Eshhar of the Department of Immunology and Regenerative Biology. Prof. Eshhar was a trailblazing scientist in the field of cancer immunotherapy, a recipient of the Israel Prize in Life Science, and an acclaimed researcher who dedicated his life to life-saving research. May he rest in peace.

Review @NatRevImmunol @CoukosGeorge Tumor-associated vasculature in T cell homing and immunity: opportunities for cancer therapy nature.com/articles/s41577-0…

#foodforthought 🍔🍕🍪🤔: the impact of infusion time of #ICIs is huge! ⏰ How many of our #immune checkpoint inhibitor clinical trials which #failed in the randomised setting may have done so ‘cos there was no stratification for this? #ASCO25 #CircadianRhythm @JordiRemon @Timothee_MD

📊 Who’s on the podium at #ASCO? Audit of 1563 oral presentations (2021–24) reveals: 🇺🇸 USA – 66.7% 🇨🇳 China – 6.3% 🇫🇷 France – 4.0% 🇬🇧 UK – 3.2% 🇨🇦 Canada – 2.3% 🇯🇵 Japan – 1.8% 🇩🇪 Germany – 1.4% 🇰🇷 South Korea – 0.8% 🌍 Africa – 0% 🌎 South America – 0.3% 🌏 Middle East – 0.1% 🎙 87% of US speakers from NCI-designated centers 🧑‍🎓 Early-career (<3 YPT): just 6% ⛔ 0 plenaries by trainees or early-career oncologists Is this global oncology? #OncologyEquity #ASCO25 #DiversityInScience #LMICvoices @ASCO @NiuSanford @GlopesMd @OncoAlert @OncBrothers

The ESGO Council is extremely saddened to learn of the untimely death of Prof Giovanni Scambia, who was a great influence to and personal friend of many of our members. A moment of silence was held today during the Congress opening ceremony in his honour. Prof Scambia touched the lives of countless patients, surgeons, fellows and others in the gynae oncology community. We extend our condolences to his family and the many, many others who are mourning his passing. His memory will live on.

CIDER now works with Seurat v5! 🎉 CIDER helps evaluate scRNA-seq integration, and we’ve updated it for the latest version. Try it out: zhiyuan-hu-lab.github.io/CID…. Let us know if you have any questions! 🚀

Novel strategies to manage CAR-T cell toxicity tinyurl.com/ye3c94na This new Review discusses management of safety issues for CAR-T cell therapies such as cytokine release syndrome, as well as druggable targets and cellular engineering strategies to develop safer CAR-T cells

#GI25 @ASCO 🌟 Practice-changing ALASCCA ph3 trial 🇸🇪 📌 ASA 160mg in PIK3CA stage II-III #CRCsm 📌 PIK3CA in 37% ➡️ HR 0.42 for 3yr DFS! @OncoAlert

Thrilled to share our recent work out today in @Nature on an mRNA therapeutic to treat pre-eclampsia! This work has been a true passion project from my time @pennbioeng in @MJMitchell_Lab, and I’m excited to continue important research in women’s health! nature.com/articles/s41586-0…

A vaccine to prevent ovarian cancer? 🧬 It’s in the works at @Oxford and patients are helping shape it. Read how our Research Network volunteers played a key role in designing this life-saving project. pulse.ly/gqc8xdjw4s #OvarianCancerPrevention #PatientInvolvement

We’re excited to announce a two-day #LabLinks on Tumor immunotherapy and immunology, organized by scientists @Ludwig_Cancer & Cell Press editors. This event is free to attend but places are limited. Register: hubs.li/Q02NRvsP0

Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma @ImmunityCP @CoukosGeorge cell.com/immunity/fulltext/S…